Time spent on disease-modifying therapy reduced the likelihood of progression in progressive-onset patients with relapse but not in those without relapse. Data were collected between January and February
No significant treatment group differences were found at 1 or 6 months of recovery on visual evoked potential P latency, best-corrected visual acuity, or low-contrast 1.
However, it is uncertain whether a bioequivalent dose of corticosteroid administered orally, which may be more cost-efficient and convenient for patients, is as effective as IV administration in the treatment of acute optic neuritis. Patients 18 to 64 years of age presenting within 14 days of acute optic neuritis onset, without any recovery at time of randomization and without history of optic neuritis in the same eye, were screened.
In total, 89 participants were screened; 64 were eligible, but 9 declined to participate. Thus, 55 participants were enrolled and randomized.
Primary analysis was unadjusted and according to the intention-to-treat principle. Secondary outcomes were the P latency at 1 month and BCVA as assessed with Early Treatment Diabetic Retinopathy Study letter scores on the alphabet chart and scores on low-contrast letters at 1 and 6 months.
The mean SD age of the cohort was Similarly, no significant group difference was found in the mean P latency recovery at 1 month. For BCVA, recovery between the groups did not reach statistical significance at 1 month or 6 months.
In addition, improvements in low-contrast 1.Sanofi Genzyme lays off at Allston Landing plant for more than $20 billion. Genzyme, which was renamed Sanofi Genzyme, essentially became the rare-disease unit of Sanofi, which employs.
Shares of Allergan, Biogen Idec and Genzyme all make moves higher, fueled by market speculation that European pharma giant Sanofi-Aventis might be considering a takeover. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Dr Morrow reported receiving honoraria for speaking, consulting, and participating on advisory boards from Biogen Idec, EMD Serono Inc, Genzyme, Novartis, and Roche.
She has acted as site principal investigator for clinical trials for Novartis. Startup Yumanity Closes on $45 Million, With Biogen and Sanofi-Genzyme BioVentures Joining In - read this article along with other careers information, tips and advice on BioSpace.
Genzyme vs Biogen Genzyme Corp. Genzyme Corporation operates as a biotechnology company worldwide. It focuses on rare genetic disease disorders, renal diseases, orthopedics, cancers, transplant and immune diseases, and diagnostic and predictive testing areas. Biogen, Merck Serono, Novartis, Roche, Sanofi, Teva Neuroscience); grant/research support (Biogen Idec, Genzyme, GW Pharma, Merck Serono, Mitsubishi, Novartis, Teva Neuroscience).
Data included in this poster were first presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), October 7.